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To the Editor:
For nearly 3 decades, the human MLL (KMT2A) gene and
its rearrangements have been investigated in many different
laboratories around the world. At our diagnostic center
(DCAL Frankfurt), our standard strategy for the identifica-
tion of MLL-r is based on two independent approaches,
namely “Multiplex” (MP)-polymerase chain reaction (PCR)
and “Long distance inverse” (LDI)-PCR approach [1]. The
MP-PCR approach is used to rapidly identify the eight most
frequent MLL fusions (AF4, AF6, AF9, AF10, ENL, ELL,
EPS15, and PTDs) which encompass ~90% of all diagnosed
MLL-r leukemia patients, while LDI-PCR is used for all
other patients (~10%). By applying both technologies, we
have accumulated 94 direct MLL-gene fusions and 247
reciprocal fusion partner genes [2]. Nearly, all breakpoints
have been identified in the major breakpoint cluster region
(BCR) of the MLL gene (MLL exons 8–14). However, some
of the patients remained negative, although they were
positively prescreened by various methods.
In order to diagnose MLL breakpoints in every patient, a
total of 2688 overlapping Illumina capture probes covering
the whole-MLL gene were designed and used to analyze a
cohort of AL patients (n= 109) where we had either limited
(n= 4; PCR positive but not sequenced) or no information
(n= 105) on their molecular status. As depicted in Fig. 1a,
we identified chromosomal rearrangements in 93 out of 109
patient cases. Sixteen patients remained MLL-r negative and
were therefore assigned as patients with “unknown status”.
The data analyses of the remaining 93 patients revealed the
following distribution: for 67 patients (72%) a breakpoint
could be analyzed in the major BCR; 5 patients (5%) dis-
played only the reciprocal der(TP) with breakpoints in exon
11 (putative CEP83-MLL spliced fusion), intron 11 (n= 3;
putative FKBP8-MLL spliced fusion, AF9-MLL, RELA-
MLL) and intron 27 (IFT46-MLL), respectively. Surpris-
ingly, an additional 21 patients (23%) had their breakpoints
outside of the major BCR, but inside a novel, minor BCR.
This novel BCR is localizing between MLL intron 19 and
exon 24 (with a clear preference for MLL intron 21–23).
Most of the new BCR cases represented MLL–USP2
gene fusions (n= 17). USP2 is localized about 1 Mbp tel-
omer to MLL at 11q23.3 and transcriptionally orientated in
direction of the centromere of chromosome 11, classifying
all these fusions as intrachromosomal inversions (see
Fig. 1b). In addition, we identified four balanced translo-
cations in the minor BCR: one patient with an USP8 fusion
(see Fig. 2 and Suppl. Figure S1), two with AF4 and one
with AF9.
MLL–USP2 and MLL–USP8 alleles seem to be restricted
to the minor BCR (see Fig. 2), because they were never
diagnosed in association with the major BCR. Most of the
reciprocal USP2–MLL fusions were scattered over a larger
region at 11q23.3 (see Fig. 2), involving also upstream
(C2CD2L) and downstream genes (USP2-AS1). Our ana-
lysis revealed also five patients with 3′-MLL deletions that
were caused by microdeletions (<200 bp), larger deletions
(up to 34 kbp), or complex rearrangements including other
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chromosomes as well (n= 4; chromosome regions 2p21,
4q13.1, 12p13.33, and 18p11.32). A detailed picture of the
investigated MLL–USP2 and MLL–USP8 and their reci-
procal fusions is shown in the Suppl. Fig. S2A–D.
All patients with a rearrangement of USP2 or USP8
fused the conserved “UCH-domain” to an extended 5′-MLL
portion (see Suppl. Fig. S1A). This may indicate that the
UCH domain has a functional importance for the resulting
MLL fusion protein. USP genes belong to a large group of
deubiquitinating proteins binding to specific target proteins
[3–5]. The USP family exhibits a ubiquitin-specific protease
(UCH domain) that is characterized by several conserved
amino acids that are summarized as CYS- and ASP-box
(see Suppl. Fig. 1B). USP2 protein deubiquinates and sta-
bilizes MDM2, leading to an enhanced degradation of p53
[6]. This in turn activates MYC, because active p53 induces
the transcription of several microRNAs that target
MYC mRNA.
MLL fusions with the conserved 3′-UCH domain of
USP2 and USP8 may change profoundly the functions of
these novel MLL fusion proteins. It has already been shown
that PHD2 [7] and PHD3/BD [8] both bind to proteins
(CDC34 and ESCASB2) that mediate the destruction of MLL
by poly-ubiquitination and proteasomal degradation. Fusing
single or all PHD domains to a der(11) product (MLL-AF9
and MLL-ENL) caused even a strong drop of their trans-
forming potential [9, 10]. This well-described degradation
mechanism of MLL may now be counteracted by the UCH
domain of MLL–USP2 or MLL–USP8, and thus, restoring
their oncogenic transformation capacity.
In our cohort, we also identified new MLL fusion partner
genes (n= 3). These novel fusion genes were SNX9
(6q25.3), USP8 (15q21.2), and SEPT3 (22q13.2). SNX9
encodes a protein known to be a member of the sorting
nexin family which contain a phosphoinositide binding
domain and are involved in intracellular trafficking. The
SNX9 protein has a variety of interaction partners, includ-
ing an adapter protein 2, dynamin, tyrosine kinase non-
receptor 2, Wiskott–Aldrich syndrome-like, and ARP3
actin-related protein 3. USP8 has diverse functions, being
Fig. 1 Overview about all analyzed patients, their molecular infor-
mation and breakpoint distribution. a Data from 109 patients which
were analyzed with NGS in percentages. Their breakpoint distribution
is displayed left (major BCR; n= 67) and right (minor BCR; n= 21).
Five patients displayed only a reciprocal fusion, while 16 cases dis-
played no MLL rearrangement. b Top: chromosome 11 is depicted
with highlighting of theMLL (red) and USP2 (green) genes. Below: all
the genes between MLL and USP; blue marked genes: additional genes
found in this study to be rearranged with MLL; orange marked genes:
genes that have been earlier described to be rearranged with MLL.
Recombinations between MLL and USP2 are caused by an inversion,
with reciprocal alleles that carry additional deletions or complex
rearrangements
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required for the internalization of liganded receptor tyrosine
kinases and stabilization of ESCRT components. The USP8
protein is thought to regulate the morphology of the endo-
some by ubiquitination of proteins on this organelle and is
involved in cargo sorting and membrane trafficking at the
early endosome stage. SEPT3 is the seventh member of the
septin family of GTPases that is fused to MLL. Members of
this family are required for cytokinesis.
A few cases of MLL–USP2 fusions have already been
described. However, these were single patient cases and
they were classified as exceptional rearrangements [11–13].
Our NGS approach allowed for the first time the recurrent
characterization of breakpoints in this novel minor BCR
region of the MLL gene. Moreover, our targeted NGS
approach enabled us to overcome the technical limitations
associated with LDI-PCR and MP-PCR approaches.
Another advantage of the targeted NGS approach is the
simultaneous identification of 3′ MLL deletions or copy
number variations. In the current study, 23 of the patients
(out of 88: 26%) had a 3′ MLL deletion. According to our
data, 3′-MLL deletions were present in both breakpoint
groups (major and minor) to a similar extent with 26.9%
and 23.8%, respectively. This seems to be much higher than
previously described (Andersson et al. [12]: 13%; Peterson
et al. [14]: 7%).
In diagnostic fluorescence in situ hybridization analyses,
these MLL–USP2 cases revealed two major patterns: (1)
loss of the 3′-MLL probe signal, and (2) a normal pattern
typical for MLL wild-type (Suppl. Table S1b, Suppl.
Fig. S3). Considering the clinical data (Suppl. Table S1a–c),
our 17 patients with MLL–USP2 were divided into 8 males
and 9 females. All of them were children, and the median
age at diagnosis was 17 months (range: 3–120 months). The
median leukocyte count was 30.4 × 109/L (range: 3.4–
324.0 × 109/L), and the disease phenotype was pre-
dominantly B-ALL (n= 12), followed by mixed-phenotype
acute leukemia (MPAL) (n= 4) and acute myeloid leuke-
mia (n= 1). The MPAL cases all had mixed myeloid and
B-cell phenotype. The patients were treated with diverse
therapy protocols. Five patients (29%) presented with
central nervous system disease, and 13 patients (76%)
had positive-minimal residual disease (MRD) levels at day
33. Prednisone response was measured in 12 patients
with a poor response in 5 patients (42%). The median
follow-up of the patients was 1.2 years (range: 0.1–11.1
years), and 2 cases died after 5 and 9 months following
Fig. 2 Detailed distribution of all breakpoints in both BCRs of MLL.
The MLL gene is depicted from exon 4 to the end. The major BCR is
marked in green, the minor BCR in red. Main breakpoint regions are
depicted in dark green/red while regions with fewer breakpoints are
depicted in light green/red. The fusions sites and the fusion partners
are shown. Information about the 5 cases with no der(11) or the 23
cases with 3′-MLL deletions are given in the box at the right bottom
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diagnosis. The remaining patients are still at first clinical
remission.
In conclusion, we have identified a minor BCR within
the human MLL gene that is recurrently associated in acute
leukemia patients with MLL–USP2 fusion alleles as well as
MLL fusion partnerships with USP8, AF4, and AF9. How-
ever, with 17 cases out of ~2500 analyzed patients the
incidence is less than 1% while still ranking fourteenth of
our updated fusion gene list (see Table 1 of reference 1).
The discovery of a second, minor BCR extends our
knowledge of the MLL-recombinome and MLL-r oncogen-
esis. Moreover, these findings will enable many labs to
make changes in their diagnostic set-up for MLL-MRD
diagnostics to ensure the best medical treatment for a group
of patients that is still very hard to cure.
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To the Editor:
Activating signaling mutations are common in acute leu-
kemia with KMT2A (previously MLL) rearrangements
(KMT2A-R) [1]. When defining the genetic landscape of
infant KMT2A-R acute lymphoblastic leukemia (ALL), we
identified a novel FLT3N676K mutation in both infant ALL
and non-infant acute myeloid leukemia (AML) [1].
FLT3N676K was the most common FLT3 mutation in our
cohort and we recently showed that it cooperates with
KMT2A-MLLT3 in a syngeneic mouse model [1, 2]. To
study the ability of FLT3N676K to cooperate with KMT2A-
MLLT3 in human leukemogenesis, we transduced human
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CD34+-enriched cord blood (CB) cells and followed leu-
kemia development immunophenotypically and molecularly
in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice.
Mice that received KMT2A-MLLT3 with or without
FLT3N676K developed a lethal leukemia, often with spleno-
megaly, thrombocytopenia, and leukocytosis, with no differ-
ence in median disease latency (107.5 and 119 days,
respectively, P= 0.48) and mice receiving FLT3N676K alone
showed no sign of disease (Fig. 1a, Supplementary Fig. 1A–E,
and Supplementary Data 1). Leukemic mice succumbed to
ALL (> 50% CD19+CD33−), AML (> 50% CD19−CD33+),
double-positive leukemia (DPL, > 20% CD19+CD33+), or
bilineal leukemia (BLL, <50% CD19+CD33−, < 50%
CD19−CD33+, and < 20% CD19+CD33+); thus, the leuke-
mias often coexisted with leukemia cells of another immu-
nophenotype (Supplementary Fig. 1F, G and Supplementary
Data 1) [3–5]. Previous studies have shown that retroviral
overexpression of KMT2A-MLLT3 in human CB cells in
NOD.CB17/Prkdcscid (NOD/SCID), NOD.Cg-Prkdcscid
B2mtm1Unc (NOD/SCID-B2m), or NSG immunodeficient mice,
primarily gives rise to ALL, sometimes to leukemias expres-
sing both lymphoid and myeloid markers or bilineal leuke-
mias, but rarely AML [3–6]. KMT2A-MLLT3-driven AML
can only be generated with high penetrance, and re-
transplanted in immunodeficient mice transgenically expres-
sing human myeloid cytokines, consistent with the idea that
external factors can influence the phenotype of the developing
leukemia [3, 6]. In agreement, most recipients that received
KMT2A-MLLT3 alone developed ALL (16/23, 69.6%) or DPL
(4/23, 17.4%) and AML was rare (2/23, 8.7%) [3, 4, 6]. By
contrast, five out of six recipients that received KMT2A-
MLLT3+FLT3N676K and that had > 60% (n= 6, range 60.4–
94.1%) of co-expressing cells, developed AML and one
developed ALL (Fig. 1b, Supplementary Fig. 1H, I, and
Supplementary Data 1). Thus, FLT3N676K preferentially drives
myeloid expansion, similar to mutant Flt3 in a syngeneic
setting [7]. FLT3 is expressed in human hematopoietic stem
and progenitor cells, with the highest expression in granulo-
cyte–macrophage progenitors (GMPs), and its signaling sup-
ports survival of those cells [8]. Combined, this suggests that
FLT3N676K affects the survival of myeloid progenitors. In this
context, it is interesting to note that FLT3 tyr-
osine kinase domain mutations are enriched in pediatric AML
with KMT2A-MLLT3 [9, 10]. Most recipients with < 10%
(n= 11, range 0.2–5.3%) of co-expressing KMT2A-MLLT3+
FLT3N676K cells succumbed to ALL, consistent with leukemia
being driven by KMT2A-MLLT3 alone. Among those with
10–60% (n= 6, range 10.9–31.6%) of co-expressing cells, a
mixture of diseases developed since leukemia could be driven
both by KMT2A-MLLT3 alone and KMT2A-MLLT3+
FLT3N676K (Fig. 1b, Supplementary Fig. 1H, I, and Supple-
mentary Data 1).
Fig. 1 FLT3N676K alters the lineage distribution of KMT2A-MLLT3-
driven leukemia. a Kaplan–Meier survival curves of NSG mice
transplanted with CD34+ cord blood cells cotransduced with KMT2A-
MLLT3+ FLT3N676K (n= 23), KMT2A-MLLT3+MSCV-GFP (n=
26, of which three died and no tissue samples could be collected),
FLT3N676K+MSCV-mCherry (n= 7), or MSCV-GFP+MSCV-
mCherry (n= 5). b Distribution of mice that succumbed to ALL,
AML, DPL, or BLL within KMT2A-MLLT3+MSCV-GFP and
KMT2A-MLLT3-mCherry+ FLT3N676K-GFP recipients divided on the
fraction of mCherry+GFP+ (<10%, n= 11; 10–60%, n= 6; or > 60%,
n= 6) cells within hCD45+ bone marrow (BM) cells. c Kaplan–Meier
survival curves of all xenograft leukemias based on their immuno-
phenotype showed an accelerated disease for AML as compared with
both ALL (P < 0.0001) and DPL (P < 0.0001). d Fish plot showing
progression of one KMT2A-MLLT3+MSCV-GFP BLL that gained a
de novo KRASG13D (VAF 17% in hCD45+ BM cells) in the secondary
recipient (h11.13-1) and targeted resequencing of hCD45+
CD19−CD33+ and hCD45+CD19+CD33− BM cells from the sec-
ondary recipient (h11.13-1) revealed the KRASG13D mutation to reside
in CD19−CD33+ leukemia cells (VAF 51%). Mantel–Cox log-rank
test, ***P ≤ 0.001, ****P ≤ 0.0001, ns= not significant
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Co-expression of KMT2A-MLLT3 and FLT3N676K pre-
ferentially expanded myeloid cells (P < 0.0001, Supple-
mentary Fig. 1J) and a high proportion of CD19−CD33+
cells at sacrifice, across the cohort, correlated with accel-
erated disease (rs=−0.6537, P < 0.0001, Supplementary
Fig. 1K, L). In agreement, AML developed with sig-
nificantly shorter latency as compared with ALL and DPL
(89 vs. 120 and 133 days, respectively, both P < 0.0001),
but not with BLL (84 days, Fig. 1c). Further, FLT3N676K-
driven AML had a tendency toward shorter survival
(median latency 78 days, range 62–117 days vs. 93 days for
KMT2A-MLLT3 alone, Supplementary Data 1).
To determine the evolution of phenotypically distinct
leukemia cells in secondary recipients, BM cells from six
primary KMT2A-MLLT3+ FLT3N676K leukemias (three
each with > 60% or 20–32% of FLT3N676K-expressing cells)
and from four primary KMT2A-MLLT3 leukemias, were re-
transplanted. All leukemias gave rise to secondary malig-
nancies and recipients that received BM from AML (n= 2)
and ALL (n= 1) with > 60% of KMT2A-MLLT3+
FLT3N676K cells had an accelerated disease onset and
maintained leukemia immunophenotype (median latency of
117 and 41 days, for the primary and secondary recipients,
respectively) (Supplementary Fig. 2A-E and Supplementary
Data 2). Thus, FLT3N676K circumvented the cytokine
dependence normally required for myeloid cells in immu-
nodeficient mice [3]. By contrast, all secondary recipients
that received BM with 20–32% KMT2A-MLLT3+
FLT3N676K cells succumbed to ALL, irrespective of disease
phenotype in the primary recipients (one AML and two
BLL). Thus, the myeloid FLT3N676K-expressing cells unex-
pectedly decreased in size, while the KMT2A-MLLT3-
expressing lymphoid cells increased to clonal dominance
(Supplementary Fig. 2F, G and Supplementary Data 2). This
suggests that the FLT3N676K-containing myeloid leukemia
population needs to be sufficiently large to expand in sec-
ondary recipients, either because they otherwise are out-
competed by the larger population of more easily engrafted
ALL cells, or because they themselves need to mediate the
permissive microenvironment that allows myeloid cells to
engraft. Similarly, in all but one of the secondary recipients
that received BM from leukemias expressing only KMT2A-
MLLT3 (two AML, one ALL, and one BLL), the disease
phenotype changed and myeloid cells did not engraft
(Supplementary Fig. 2H-J and Supplementary Data 2).
In the secondary recipient with maintained immuno-
phenotype (a BLL, h11.13-1), the myeloid cells unexpect-
edly expanded from 38% to close to 50% (Fig. 1d and
Supplementary Data 2). This suggested that the myeloid
cells had acquired a de novo mutation that allowed serial
transplantation, similar to what was observed for
FLT3N676K. Strikingly, targeted sequencing of AML-
associated genes on hCD45+ BM from this mouse
identified a KRASG13D in 34% of the cells. Resequencing of
hCD45+CD19−CD33+ and hCD45+CD19+CD33− BM
showed that KRASG13D was present exclusively in the
myeloid population and based on the variant allele fre-
quency of 51%, that all cells carried the mutation (Fig. 1d
and Supplementary Table 1, 2). Further, KRASG13D likely
arose independently in h11.13-1 as no mutation was iden-
tified, at the level of our detection, in the primary (h11.13)
or in a separate secondary recipient (h11.13-2) from the
same primary mouse (h11.13) that developed ALL (Sup-
plementary Table 2 and Supplementary Data 2).
Gene expression profiling (GEP) followed by principal
component analysis (PCA) showed that the leukemias
segregated based on their immunophenotype, with an evi-
dent separation between leukemias and normal hemato-
poietic cells (Fig. 2a, Supplementary Fig. 3A, B, and
Supplementary Table 3). All leukemias expressed high
levels of known KMT2A-R target genes and showed
enrichment of gene signatures associated with primary
KMT2A-R leukemia, indicating that they maintain a GEP
representative of human disease (Supplementary Fig. 3C, D
and Supplementary Data 3–6). In line with the hypothesis
that KMT2A-MLLT3 DPL cells are ALL cells with aberrant
CD33 expression, they clustered closely with ALL cells.
Both populations expressed high levels of ALL-associated
cell surface markers and lymphoid transcription factors
(Fig. 2a and Supplementary Fig. 3B, E-H). Further, CD33
and other AML-associated cell surface markers and key
myeloid transcription factors, all showed lower expression
in DPL cells as compared with normal myeloid- and AML
cells (Supplementary Fig. 3G-I).
By correlating the GEPs of the xenograft leukemias to
those of normal hematopoietic cells [11], DPL and ALL
were found to resemble normal common lymphoid pro-
genitors (CLPs) and AML cells normal GMPs (Fig. 2b).
Further, ALL and DPL cells had significantly higher
expression of the transcription factor CEBPA as com-
pared with normal lymphoid cells which lacked CEBPA
expression (Fig. 2c). CEBPA drives myeloid programs
and is expressed in most hematopoietic progenitors, in
particular in GMPs, with CLPs lacking CEBPA expres-
sion (Fig. 2c) [11]. Finally, to link the GEPs of our
xenograft leukemias to those of pediatric KMT2A-R
leukemia, we utilized a dataset of pediatric B-cell pre-
cursor ALL (BCP-ALL) [12]. Multigroup comparison
visualized by PCA showed that KMT2A-MLLT3 DPL
and ALL mainly resembled KMT2A-R BCP-ALL
(Fig. 2d), again highlighting that the xenograft leuke-
mias resemble human leukemia.
We next studied the transcriptional changes induced by
FLT3N676K in KMT2A-MLLT3 AML cells. Gene set
enrichment analysis (GSEA) revealed enrichment of gene
sets connected to the Myc-transcriptional network, cell
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cycle, and proliferation when compared with KMT2A-
MLLT3 AML (Supplementary Data 7). Similar to our pre-
vious findings in a syngeneic KMT2A-MLLT3 mouse model
[2], the Myc-centered program [13] was not linked to the
pluripotency network (Supplementary Fig. 4A and Sup-
plementary Data 8, 9). Since FLT3 mutations activate
mitogen-activated protein kinase (MAPK) signaling [14],
we investigated if FLT3N676K increased expression of MEK/
ERK-pathway genes, by studying the expression of known
transcriptional output genes and negative feedback reg-
ulators of the pathway [15]. Indeed, enrichment of MEK/
ERK-associated genes was evident in FLT3N676K-expressing
cells, suggesting that FLT3N676K allows cells to overcome
normal feedback regulation, leading to sustained signaling
[15] (Supplementary Fig. 4B). Finally, FLT3N676K-expres-
sing AML showed preserved transcriptional changes to
those seen in infant KMT2A-AFF1 ALL with activating
mutations [1] (Supplementary Fig. 4C). Thus, FLT3N676K
Fig. 2 DPL cells are ALL cells with aberrant CD33 expression.
a Hierarchical clustering based on multigroup comparison of myeloid
CD19−CD33+ leukemia cells from KMT2A-MLLT3+MSCV-GFP
(KM-CD33) and KMT2A-MLLT3+ FLT3N676K (KM+ FLT3N676K-
CD33), lymphoid CD19+CD33− leukemia cells from KMT2A-
MLLT3+MSCV-GFP (KM-CD19), and double-positive CD19+
CD33+ leukemia cells from KMT2A-MLLT3+MSCV-GFP (KM-
CD19,CD33), as well as normal myeloid- CD19−CD33+ (normal
CD33) and lymphoid CD19+CD33− (normal CD19) cells from
MSCV-GFP+MSCV-mCherry using 637 variables (P= 2.2e−15,
FDR= 4.9e−14). b Supervised (1500 variables, P= 3.6e−4, FDR=
3.1e−3) PCA based on human hematopoietic stem cells (HSC), mul-
tipotent progenitors (MPP), lymphoid-primed multipotent progenitors
(LMPP), common myeloid progenitors (CMP), granulocyte–
macrophage progenitors (GMP), and common lymphoid progenitors
(CLP) [11]. Samples with leukemia cells from KM-CD33, KM+
FLT3N676K-CD33, KM-CD19, and KM-CD19,CD33 were inserted into
the same PCA (still based solely on the normal populations [11]),
revealing that AML cells mainly resembled GMPs and that both ALL
and DPL mainly resembled CLPs. c CEBPA expression (FPKM log2)
within sorted leukemia, normal populations, and within HSC, MPP,
LMPP, CMP, GMP, CLP, MEP, monocytes, and B cells [11].
d Supervised (1501 variables, P= 3.3e−10, FDR= 3.1e−9) PCA based
on pediatric BCP-ALL with ETV6-RUNX1, high hyperdiploid (HeH),
TCF3-PBX1, or KMT2A-R [12]. Samples with leukemia cells from
KM-CD19 and KM-CD19,CD33 were inserted into the same PCA
(still based solely on the pediatric BCP-ALL populations [12]). Mann–
Whitney U test used in (c), *P ≤ 0.05, **P ≤ 0.01, ns= not significant
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may circumvent the cytokine dependence seen for myeloid
cells in immunodeficient mice by providing constitutive
active signaling promoting cell proliferation, likely through
the MAPK/ERK pathway.
Herein, we demonstrate that co-expression of KMT2A-
MLLT3 and FLT3N676K in human CB cells primarily causes
AML and thus alters the lineage distribution of KMT2A-
MLLT3-driven leukemia. AML could only be serially
transplanted with maintained immunophenotype in the
presence of FLT3N676K. This is consistent with the idea that
activated signaling allows myeloid cells to more efficiently
engraft and maintain their self-renewal. In agreement, we
identified a de novo KRASG13D in myeloid KMT2A-MLLT3-
expressing cells that had expanded upon secondary trans-
plantation. Altogether, this shows that constitutively active
signaling mutations can substitute for external factors and
influence the phenotype of the developing KMT2A-R leu-
kemia, at least in xenograft models.
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To the Editor:
Efficient and specific removal of malignant cells is the
ultimate goal of cancer therapy. The current rapid devel-
opment of chimeric antigen receptor T-cell (CAR-T-cell or
CART) therapy potentially provides high efficiency and
allows long-term surveillance, which have greatly extended
the frontier of leukemia treatment.
T-cell leukemia/lymphoma accounts for 15–25% of the
incidence of malignant lymphoid diseases and represents
22 clinicopathologic entities in the most recent classifi-
cation [1–3]. Recently, researchers have started to inves-
tigate approaches using chimeric antigen receptor T-cells
(CAR-T-cells or CARTs) to treat T-cell leukemia/lym-
phoma by targeting common antigens such as CD4, CD5,
TRBC1/2, and the chemokine receptor CCR4 [4–7]. The
major hallmark of T-cell leukemia is the clonal expansion
of malignant lymphocytes [8–10], which is both a char-
acteristic and diagnostic marker [11, 12]. Given the vast
diversity of the immune repertoire, leukemia cell germ-
lines from each patient have a unique T-cell receptor
(TCR) on the cell surface that distinguishes these cells
from normal T-cells. We hypothesized that targeting
complementarity-determining region 3 (CDR3) on TCRs
on leukemia cells by personalized tumor-specific CARTs
would be a valid and superior approach that may offer
higher precision and lower off-tumor toxicity than current
treatment approaches. Recent advancements in next-
generation sequencing (NGS) technology have enabled
researchers to investigate TCR diversity with unprece-
dented depth and efficiency. Here, we propose a novel
pipeline based on epitope screening technology aimed at
isolating unique CDR3 regions from patients with leuke-
mia/lymphoma for the subsequent redirection of human T-
cells toward malignant epitopes. We assumed that the
screening of combinatorial single-chain variable fragment
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(scFv) libraries derived from the immune repertoire of
cancer patients would allow us to select malignancy-
specific epitopes that could facilitate the generation of
redirected tumor-specific T-cells. We established a plat-
form spanning from clinical pathology to antigen identi-
fication and from targeted scFv screening to in vitro/
in vivo validation, and the entire process can be com-
pleted in a relatively short time frame (Fig. 1a). We
believe that clonal T-cell CDR3-selective CART therapy
is a viable approach for further clinical development, with
the potential for extrapolation to B-cell malignancies.
We collected pathological samples from nine leukemia
patients (four with T-cell acute lymphoblastic leukemia (T-
ALL) and 5 with T-cell non-Hodgkin lymphoma (T-NHL),
Supplementary Table S1) pathologically confirmed by his-
tology and flow cytometry, and four healthy donors (normal
controls) to study TCR diversity. Isolated cells (as well as
Jurkat and MOLT-4 cells as controls) were used for gDNA
extraction, amplification of the CDR3 region of TCRβ chain
sequences and NGS analysis (Supplementary Fig. S1,
Table S2). Consistent with previous reports [13], the TCR
diversity of T-cells from leukemia patients showed an
abnormal predominance of CDR3 sequences (the frequency
ranged from 7 to 94%), while no single clone exhibited a
frequency of higher than 2% in T-cells from healthy donors
(Fig. 1b). Identified dominant, unique CDR3 sequences
from the leukemia, Jurkat and MOLT-4 cells were chemi-
cally synthesized and used for further applications.
Seminal studies imply that a patient’s immune surveil-
lance system may harbor antibodies against neoepitopes on
pathogens or malignant cells [14]. We hypothesized that the
antibody library derived from a leukemia patient could be
uniquely useful for the selection of antibodies against the
patient’s malignant TCRs. Therefore, we constructed a
phage combinatorial antibody scFv library from 56 patients
and 20 healthy donors. Furthermore, we performed phage
personalized
anti-
immobilized
T-cellsmalignant
Isolated
patient
T-cells
J-CDR3-scFv
P1-CDR3-scFv
Healthy donor T-ALL (Patient #1) MOLT-4
P6-CDR3-scFv
P8-CDR3-scFv
Patient #6 biopsy sample
Patient #8 biopsy samplePatient #1 biopsy sample
isotype control
isotype control
T-cell
Fig. 1 a Workflow for the selection of ligands for personalized CDR3-
selective CART therapy for lymphoma and leukemia. A biopsy sample
from a patient with lymphoma or leukemia was isolated, and the
collected tumor cells were utilized for identification of the TCR
CDR3 sequence on malignant T cells. The identified CDR3 sequences
were chemically synthesized and used for scFv phage panning.
Selected scFv clones were sequenced and transferred to the CAR
backbone. Autologous T cells were modified by personalized patient
CDR3-selective CARs. b NGS analysis of the TCR repertoire from
Jurkat, MOLT-4, patient biopsy and healthy donor cells. Representa-
tive Circos plots of the frequencies of Vβ and Jβ usage and
combinations of unique productive templates. The width of the band is
proportional to the frequency. c Flow cytometric analysis of Jurkat cells
and patient #1 biopsy sample cells stained by GFP fusions of the scFvs
specific to the CDR3 regions of the Jurkat cells (J-CDR3-scFv) or
Patient#1 malignant T cells (P#1-CDR3-scFv). d Immunohistochemistry
analysis of the patient#6 biopsy sample stained by GFP fusions of the
scFv specific to the CDR3 regions of the Patient#6 malignant T cells
(P#6-CDR3-scFv and isotype antibody control. e Immunohistochemistry
analysis of the patient#8 biopsy sample stained by GFP fusions of the
scFv specific to the CDR3 regions of the Patient#8 malignant T cells
(P#6-CDR3-scFv) and isotype antibody control
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display screening of individual peptides. After three rounds of
selection, we obtained specific scFvs against CDR3 peptides
(Supplementary Table S3). The results of previous structural
studies suggest that some CDR3 fragments form rather
sophisticated tertiary conformations, which may not be fully
represented by chemically synthesized linear peptides. To
validate whether our selected antibodies could recognize
TCRs harboring the CDR3 sequences, selected scFv-GFP
fusion proteins were used to stain the biopsy samples from the
patients. The scFv fusion proteins specifically labeled both
dispersed cancer cells (Jurkat and patient #1-T-ALL) (Fig. 1c)
and lymphoma biopsy (patient #6-peripheral T-cell lymphoma
(PTCL) and patient #8-angioimmunoblastic T-cell lymphoma
(AITL)) (Fig. 1d, e). To analyze off-target specificity, clinical
bone marrow, liver, spleen, and lymph node tissue specimens
were stained with selected scFv-GFP fusion proteins. Immu-
nohistochemical examination did not show any detectable off-
target binding of the CDR3-specific scFvs (Supplementary
Fig. S2). Thus, we concluded that patient B cell repertoire-
aided combinatorial antibody library screening is a valid
approach to identify antibodies against TCR CDR3 regions on
malignant cells for subsequent therapeutic applications.
To explore the possibility of personalized immunother-
apy with the CAR approach, the library-selected CDR3-
specific scFvs against TCRs on MOLT-4 cells, Jurkat cells,
and cells from patient #1 were cloned into lentiviral vectors
encoding second-generation CARs and named J-CAR,
MOLT-4-CAR and P#1-CAR, respectively. The corre-
sponding lentiviruses were produced and used for trans-
duction of activated primary human T-cells.
We next determined whether T-cells modified with the
P#1-CAR and J-CAR constructs exhibited specific cyto-
toxicity in vitro. We incubated CARTs with biopsy cells
from patient #1, Jurkat cells or modified Jurkat cells
expressing TCRs with the replaced CDR3 from the tumor
cells from patient #1 (P1-CDR3-Jurkat). After 24 h of
coculture, activated human CDR3-specific T-cells respon-
ded to their corresponding Jurkat or patient malignant T-
cells by secreting IL-2 and IFN-γ, as well as undergoing
highly efficient cell lysis (Fig. 2a).
To validate the specificity of the CARTs targeting CDR3
epitopes on malignant cells, we analyzed the TCR repertoire
diversity before and after coincubation of the CDR3-selective
CARTs or control CART-cells with biopsy cells from patient
#1 or Jurkat cells. By ranking the frequency of the V and J
regions of the TCRs, we found that control CARTs did not
alter the frequency of TCR sequences on malignant cells
(Fig. 2b, left panel). However, both J-CARTs and P#1-
CARTs drastically reduced the percentage of malignant T-cell
clones (Fig. 2b, right panel), suggesting the safety and sub-
stantial therapeutic potential of TCR targeting.
The encouraging results described above prompted us to
investigate whether this approach could be further validated
in vivo. We tested the efficacy of J-CARTs, MOLT-4-
CARTs, and P#1-CARTs in a disseminated leukemia model
by i.v. engrafting the corresponding target cell lines (Jurkat,
MOLT-4 or P1-CDR3-Jurkat cells expressing luciferase)
into immunodeficient NOD mice. Two days after tumor
inoculation, animals from all experimental groups were
treated with CARTs specific to the TCRs on the injected
cells or control CARTs with irrelevant CDR3 specificity.
Injection of J-CARTs, MOLT-4-CARTs, and P#1-
CARTs significantly reduced the tumor burden in animals
and led to cancer cell elimination, while animals injected
with control CARTs hosted a progressively increasing
number of malignant cells (Fig. 2c). Indeed, compared with
animals in the control CART-treated groups, animals in the
CDR3-specific groups exhibited improved body weight and
extended survival (Fig. 2d).
We demonstrated for the first time that targeting the CDR3
regions of malignant T-cell clones by cell therapy is a viable
approach to eliminate leukemia cells. Due to its intrinsic
uniqueness, the CDR3 region has historically been an intri-
guing target with much historical discussion. A few attempts
have been made to use this region as the antigen for a cancer
vaccine [15]. Due to the clonal nature of leukemia cells and
the uniqueness of a given CDR, targeting CDR3 should offer
a few advantages not offered by targeting common antigens:
(1) Lower “on-target, off-tumor” effect; (2) Minimized impact
on a patient’s immune system during treatment; and (3) Great
capacity for development as a personalized treatment that can
be tailored to individual needs, as a percentage of patients do
not respond well to existing therapies with common targets. In
the current study, we validated the idea of using CARTs as
targeting agents and observed excellent continuous efficacy as
well as specificity. Combining CDR3 targeting with the
CART approach provides a solution for a substantial portion
of patients with T-cell leukemia and lymphoma, with sup-
posedly minimized side effects. The potential problems to be
solved in the future include establishing efficient and
streamlined good laboratory practice (GLP)-level CDR3
binder discovery and good manufacturing practice (GMP)-
level personalized CART manufacturing and decreasing the
financial burden for individual patients. However, these issues
may be short-lived as technologies develop rapidly.
Nevertheless, after validation of this strategy to eliminate
pathological T-cells ex vivo and in vivo, we envisage this
approach as a generally useful alternative and supplement to
the popular approach of common antigen targeting to treat
T-cell malignancies, especially considering its safety.
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Fig. 2 a P#1-CARTs and J-CARTs were cocultured with biopsy cells
from patient #1, Jurkat cells or Jurkat cells with the CDR3 region
replaced from malignant cells of patient #1. CARTs with different
CDR3 specificities were used for comparison. Cytotoxicity was
determined by measuring lactate dehydrogenase release after 6 h. IL-2
and IFN-γ cytokine release was measured after 24 h. All experiments
were performed in triplicate wells for each condition and repeated at
least twice. b TCR repertoire diversity after 24 h of coincubation of
CDR3-selective CARTs or irrelevant CARTs with biopsy cells from
patient #1 or Jurkat cells. Survival plots c and imaging results d for
animals inoculated with Jurkat, MOLT-4 or P1-CDR3-Jurkat cells
(0,5*106/mouse) and treated by i.v. injection of 5 × 106 CARTs spe-
cific to the CDR3 region of the targeted cells or control CARTs (n=
12 mice per group). Overall survival curves were plotted using the
Kaplan-Meier method and compared using the log-rank (Mantel-Cox)
test. Statistical significance: *p < 0.05, **p < 0.01
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To the Editor:
The t(9;22) translocation results in the expression of the
constitutively active BCR-ABL1 tyrosine kinase. It is
detected in chronic myelogenous leukemia (CML) and in
~30% of adult acute lymphoblastic leukemia (ALL) patients
[1]. Thus, Ph+ ALL is not only the largest genetically
defined subgroup of ALL, but also characterized by a poor
prognosis [2]. The two major protein isoforms of Bcr-Abl
are p210 and p190. Whereas the shorter p190 isoform is
specific for Ph+ ALL, the longer p210 isoform causes CML,
but is also present in ~30% of Ph+ ALL patients [1, 3].
BCR-ABL1 was the first oncogene targeted successfully
with the tyrosine kinase inhibitor (TKI) imatinib,
which results in durable remissions in most CML patients
and increased remission rates and survival in Ph+ ALL
patients. Still, resistance to imatinib occurs particularly
frequently in Ph+ ALL. Several next-generation TKIs were
developed to address TKI resistance and intolerance [4].
Various TKI resistance mechanisms, including dozens
of Bcr-Abl mutations, were described, but causes for
resistance are still elusive in a significant portion of
patients [5].
Deregulation of protein tyrosine phosphatases (PTP)
plays an important role in maintaining a wide range of
cancers. The ability of tyrosine phosphatases to antagonize
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oncogenic tyrosine kinases makes them candidate tumor
suppressors. We previously showed that deregulation of
PTP1B causes resistance in Ph+ leukemias [6]. The phos-
phatase Sts-1 (suppressor of T-cell receptor signaling 1,
encoded by the human UBASH3B gene) was found to be
transcriptionally upregulated in Ph+ ALL as compared with
Ph− ALL patients [7]. Notably, Sts-1 also is one of the most
prominent interactors of Bcr-Abl as determined by a sys-
tematic interaction proteomics screen [8]. In two recent
independent studies, Sts-1 was found to interact
more strongly with the Bcr-Abl p210 isoform than with
p190 and to be phosphorylated in Bcr-Abl expressing cells
[9, 10]. Sts-1 and its only human and mouse paralogue, Sts-
2 (UBASH3A), comprise an N-terminal ubiquitin-asso-
ciated (UBA) domain, an Src homology 3 (SH3) domain
and a C-terminal phosphoglycerate mutase (PGM) domain,
which has structural homology with the histidine phos-
phatase superfamily. It was demonstrated that Sts-1 (and to
a lesser extent Sts-2) possesses tyrosine phosphatase
activity [11]. Strikingly, Sts-1 is a negative regulator of
several tyrosine kinase pathways, including not only EGFR
and PDGFR, but also ZAP-70 and SYK, thereby antag-
onizing T- and B-cell receptor signaling, respectively [12,
13]. As genetic and functional perturbation of kinase–
phosphatase networks have been implicated in oncogenesis
and based on our previous expression and proteomics data,
we reasoned that the interaction between the Bcr-Abl kinase
and the Sts-1 phosphatase may contribute to leukemogen-
esis. We therefore investigated the functional relationship
between these two proteins, in particular the ability of Sts-1
to dephosphorylate Bcr-Abl and how it may contribute to
TKI resistance in Ph+ ALL patients.
To study the interaction of Bcr-Abl p190 with Sts-1 and
its dependence on kinase activity in Ph+ ALL cells, we
performed coimmunoprecipitation (co-IP) assays of the
endogenous p190 and Sts-1 in Sup-B15 cells either in the
absence or presence of imatinib. Sts-1 binding to p190 was
largely independent of the Bcr-Abl activation status, as their
interaction was only mildly reduced in cells following
exposure to imatinib (Fig. 1a). These data were confirmed
by co-IP assays using murine Ba/F3 cells stably expressing
p190 or Sts-1 as an independent cell-line model. p190
interacted with endogenous or overexpressed Sts-1 regard-
less of the activation status of Bcr-Abl (Fig. 1b, c).
In order to map the interaction mode of the two proteins,
we first determined if Sts-1 binds to the Bcr- or Abl-portion
of Bcr-Abl p190. These experiments were performed in Ba/
F3 cells upon coexpression of Sts-1 with full-length Bcr-
Abl, the Abl-portion (#ABL1) only, the Bcr oligomerization
domain directly fused to the Abl-portion (BCC-ABL1) or
only the Bcr-portion (BCR; Fig. 1d). These experiments
showed that Sts-1 binding was mediated by the Abl-portion
of Bcr-Abl, as all Abl-containing constructs, but not the
Bcr-portion alone, bound Sts-1 (Fig. 1d). To map the Sts-1
domains that are required for binding, we performed co-IP
assays using loss-of-function point mutations in all domains
of Sts-1, including the UBA (W72E), SH3 (W295A), and
PGM (H391A) domains (Fig. 1e). To further delineate the
requirements for binding to Bcr-Abl, we also assayed these
mutants in combination with Bcr-Abl mutants with either
abolished kinase activity (ΔK; D382N mutation) or a
deletion in the C-terminal last exon region (ΔLE). Sts-1
interacted with the N-terminal part of the Abl-portion of
Bcr-Abl encompassing the SH3-SH2-kinase domain unit
(Fig. 1e). This interaction was independent of the activation
status and the various protein–protein interaction motifs in
the C-terminal last exon region of Bcr-Abl. Furthermore,
the interaction does not require a functional UBA-, SH3-, or
PGM-domain of Sts-1 (Fig. 1e).
To study a possible functional interdependence of the
Bcr-Abl/Sts-1 kinase–phosphatase interaction, we first
investigated how Sts-1 may regulate Bcr-Abl kinase activity
and autophosphorylation at different tyrosine (Y) residues:
Y177 in the Bcr-portion is critical for Ras-MAPK signaling,
whereas Y245 and Y412 in the Abl-portion are important
markers for kinase activation [14]. Thus, we examined the
autophosphorylation of Bcr-Abl in Ba/F3 cells in the pre-
sence and absence of Sts-1. In line with its binding prop-
erties, Sts-1 caused strong dephosphorylation of Bcr-Abl at
Abl-Y245 and Abl-Y412, whereas Bcr-Y177 was only
mildly dephosphorylated (Fig. 1f). In a second step, we
cotransfected HEK293 cells with either Bcr-Abl or an
oligomerization-deficient mutant (ΔCC-Bcr-Abl) together
with either wild-type or a phosphatase-dead (H391A) Sts-1
[11]. We found that Sts-1 dephosphorylates both Bcr-Abl
and itself, and that Sts-1 is a kinase substrate of Bcr-Abl. In
fact, Sts-1 dephosphorylated Bcr-Abl and ΔCC-Bcr-Abl
strongly and equally well (Fig. 1g). Conversely, only
phosphatase-dead Sts-1, but not wild-type Sts-1, was
strongly phosphorylated in the presence of Bcr-Abl,
demonstrating that Sts-1 is able to dephosphorylate itself
(Fig. 1g).
Given that Sts-1 may regulate kinase activity of Bcr-Abl
by modulating its autophosphorylation, we next investi-
gated whether Sts-1 impacts on cell proliferation in IL-3-
independent Ba/F3 cells expressing wild-type (wt) Bcr-Abl
or the gatekeeper mutation T315I, which conveys resistance
to multiple TKIs. These cells were retrovirally transduced
with GFP or Sts-1-GFP, and proliferation competition
assays were performed over the course of 12 days. The
expression of GFP alone did not alter the proliferation of
BCR-ABL expressing Ba/F3 cells as revealed by the con-
stant percentage of GFP positive cells (Fig. 2a). In contrast,
expression of Sts-1-GFP reduced the proliferation of Ba/F3
cells expressing Bcr-Abl wt and T315I. Concomitant
treatment with 1 µM imatinib further decreased proliferation
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of Bcr-Abl wt, but, as expected, not Bcr-Abl-T315I cells
(Fig. 2a). These results indicate that Sts-1 activity nega-
tively regulates cell proliferation induced by Bcr-Abl wt and
T315I.
To assess the role of Sts-1 in Bcr-Abl-driven leukemo-
genesis, we examined the induction of Bcr-Abl p210-
induced CML-like disease in wt vs. Sts-1/Sts-2 double-
knockout bone marrow cells using a transduction/trans-
plantation model. The absence of Sts-1/Sts-2 decreased the
survival of recipient mice significantly and further aggra-
vated the pronounced splenomegaly observed in mice
transplanted with Bcr-Abl-expressing wt cells (Fig. 2b).
Fig. 1 The Sts-1 phosphatase interacts with and dephosphorylates Bcr-
Abl. a SupB15 was treated with imatinib (2 µM for 6 h). ABL1
immunoprecipitates (left panel) from total cell lysates and 5% input
fraction (right panel) were immunoblotted with the indicated anti-
bodies. b Ba/F3 cells transduced with STS-1 were additionally trans-
duced with BCR-ABL1 and treated with imatinib (1 µM for 6 h). STS-
1 immunoprecipitates (right panel) from total cell lysates and 5% input
fraction (left panel) were immunoblotted with the indicated antibodies.
c Ba/F3 cells transduced with BCR-ABL1 were additionally trans-
duced with STS-1 and treated with imatinib (1 µM for 6 h). ABL1
immunoprecipitates (right panel) from total cell lysates and 5% input
fraction (left panel) were immunoblotted with the indicated antibodies.
d Ba/F3 cells transduced with full-length Bcr-Abl, the Abl-portion
(#ABL1) only, the Bcr oligomerization domain directly fused to the
Abl-portion (BCC-ABL1) or only the Bcr-portion (BCR) was addi-
tionally transduced with STS-1. ABL1 (upper panels) and STS-1
(lower panels) immunoprecipitates from total cell lysates were
immunoblotted with the indicated antibodies. e HEK293 cells were
cotransfected with BCR-ABL1 wt, Bcr-Abl kinase-dead (D382N;
BCR-ABLΔK) or BCR-ABL1 lacking the C-terminal last exon region
(BCR-ABLΔLE) with STS-1 wt and point mutations in functional
domains (UBA (W72E), SH3 (W295A), and PGM (H391A)). ABL1
immunoprecipitates were analyzed by immunoblotting using the
indicated antibodies. f Ba/F3 cells retrovirally expressing BCR-ABL1
were transfected with STS-1 or empty vector. Whole-cell lysates were
then analyzed with the indicated antibodies. g HEK293 cells were
cotransfected with BCR-ABL1 wt or an oligomerization-defective
BCR-ABL1 lacking the coiled-coil domain (ΔCC-BCR-ABL1) with
either STS-1 wt or a phosphatase-dead STS-1 mutant (H391A). Total
cell lysates were analyzed by immunoblotting using the indicated
antibodies
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These results indicate that Sts-1/Sts-2 are functionally
relevant negative regulators of Bcr-Abl-dependent leuke-
mogenesis in a CML mouse model.
The glucocorticoid dexamethasone and Sts-1 seem to
regulate several common signaling pathways: Both inhibit
T-cell receptor (TCR) signaling by regulating TCR
expression and Sts-1 additionally inhibits certain down-
stream effectors [15]. In order to harness the therapeutic
potential of Sts-1’s ability to inhibit growth of Bcr-Abl-
positive cells, we explored whether dexamethasone may
alter Sts-1 expression and activity. Exposure of Sup-B15
and Sup-B15RT cells to clinically relevant concentrations
of dexamethasone increased Sts-1 expression over time,
accompanied by decreased Bcr-Abl autophosphorylation in
Sup-B15 cells (Fig. 2c, d), indicating that it increases the
sensitivity of Bcr-Abl-transformed cells to TKIs. In cell
proliferation assays, concomitant treatment with dex-
amethasone and imatinib showed stronger inhibition than
each drug alone in both Sup-B15 and Sup-B15RT cells
(Fig. 2e).
Deregulation of the tyrosine phosphatase Sts-1 may be an
important and pharmacologically targetable mechanism for
Bcr-Abl mutation-independent resistance. Upregulation of
Sts-1 in Ph+ ALL together with its direct interaction with
both p190 and p210 Bcr-Abl strongly suggests a functional
deregulation of protein phosphorylation similar to that we
previously showed for PTP1B [6]. The fact that its normal
function can be restored by ectopic overexpression not only
indicates a central role for Sts-1 in the regulation of Bcr-Abl
but also that the deregulation of Sts-1 is based on a loss of
balance between Bcr-Abl kinase and Sts-1 phosphatase
activity. This establishes the upregulation of Sts-1 by drugs,
such as dexamethasone, as a valid therapeutic approach for
increasing the sensitivity to TKIs.
In conclusion, we delineated the molecular interaction
mode of the Sts-1 phosphatase with the Bcr-Abl kinase and
provide strong evidence that Sts-1 is a negative regulator of
Bcr-Abl signaling, cell proliferation, and leukemogenesis.
In addition, the parallel study by Udainiya et al. (cosub-
mitted) shows a broad impact of Sts-1 on the Bcr-Abl
Fig. 2 Sts-1 negatively regulates Bcr-Abl-dependent leukemogenesis
and cell proliferation and its expression is upregulated by dex-
amethasone. a The proliferation competition assay with Ba/F3 cell
transduced with BCR-ABL1 wt or T315I in the absence or presence of
STS-1 expression and without (left) or with (right) imatinib treatment
(2 µM). BCR-ABL1-positive cells are marked with GFP and the
relative changes in GFP expression were measured by FACS and
followed over time. Mean values ± SD from three replicates are shown.
b Equal amounts of primary murine Lin− c-Kit+ Sca-1+ cells from wt
or Sts-1/Sts-2 knockout animals expressing BCR-ABL1 were injected
in lethally irradiated recipient mice (n= 8 for each group). Overall
survival of transplanted mice was monitored over 60 days. P-value=
0.014 was calculated using a logrank (Mantel–Cox) test. Representa-
tive spleens from control mice, BCR-ABL1/Sts-1/2 wt and BCR-
ABL1/Sts-1/2 KO mice are shown. c SupB15 Ph+ ALL cells and their
imatinib-resistant subline SupB15RT were exposed to 10−7 M dex-
amethasone, and STS-1 expression was investigated at the given time
points. α-Tubulin was used as loading control. d SupB15 Ph+ ALL
cells and their imatinib-resistant subline SupB15RT were exposed to
10−7M dexamethasone, and the effect of increasing expression of STS-
1 on BCR-ABL1 phosphorylation was investigated by an anti-p-Tyr
antibody. e SupB15 and SupB15RT were exposed to imatinib (1
µM) and 10−7M dexamethasone alone or in combination and pro-
liferation was analyzed by the XTT assay. The bars represent the mean
(±SEM) of three independent experiments, each performed in tripli-
cates. Statistical significance was calculated using student’s t test.
***p ≤ 0.001
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phosphoproteome network and precisely delineated the Sts-
1 interactome using quantitative functional proteomics
techniques. Furthermore, we show that modulation of Sts-1
expression by dexamethasone influences TKI sensitivity of
Ph+ ALL cells. Therefore, the inclusion of dexamethasone
for therapy regimens in Ph+ ALL for may increase sensi-
tivity to TKIs by upregulating Sts-1.
Acknowledgments This work was supported by the Swiss National
Science Foundation (grant 31003A_140913; OH) and the Cancer
Research UK Experimental Cancer Medicine Centre Network, Cardiff
ECMCI, grant C7838/A15733. We thank N. Carpino for the Sts-1/2
double-KO mice.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Deininger MW, Goldman JM, Melo JV. The molecular biology of
chronic myeloid leukemia. Blood. 2000;96:3343–56.
2. Ottmann OG, Pfeifer H Management of Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Hematol Am Soc Hematol Educ Program. 2009;1:371–81.
3. Reckel S, Gehin C, Tardivon D, Georgeon S, Kukenshoner T,
Lohr F, et al. Structural and functional dissection of the DH and
PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat Commun.
2017;8:2101.
4. Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of
ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer
Res. 2012;72:4890–5.
5. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the
limits of targeted therapy in chronic myeloid leukaemia. Nat Rev
Cancer. 2012;12:513–26.
6. Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J,
Myloch S, et al. Inhibition of phosphotyrosine phosphatase
1B causes resistance in BCR-ABL-positive leukemia cells to
the ABL kinase inhibitor STI571. Clin Cancer Res. 2006;12:
2025–31.
7. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe
JM, et al. Differential gene expression patterns and interaction
networks in BCR-ABL-positive and -negative adult acute lym-
phoblastic leukemias. J Clin Oncol. 2007;25:1341–9.
8. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M,
Kocher T, et al. Charting the molecular network of the drug target
Bcr-Abl. Proc Natl Acad Sci USA. 2009;106:7414–9.
9. Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe
D, et al. Differential signaling networks of Bcr-Abl p210 and p190
kinases in leukemia cells defined by functional proteomics. Leu-
kemia. 2017;31:1502–12.
10. Cutler JA, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S,
Nirujogi RS, et al. Differential signaling through p190 and p210
BCR-ABL fusion proteins revealed by interactome and phos-
phoproteome analysis. Leukemia. 2017;31:1513–24.
11. Mikhailik A, Ford B, Keller J, Chen Y, Nassar N, Carpino N. A
phosphatase activity of Sts-1 contributes to the suppression of
TCR signaling. Mol Cell. 2007;27:486–97.
12. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H,
Geiger TL, et al. Regulation of ZAP-70 activation and TCR sig-
naling by two related proteins, Sts-1 and Sts-2. Immunity.
2004;20:37–46.
13. Raguz J, Wagner S, Dikic I, Hoeller D. Suppressor of T-cell
receptor signalling 1 and 2 differentially regulate endocytosis and
signalling of receptor tyrosine kinases. FEBS Lett.
2007;581:4767–72.
14. Hantschel O. Structure, regulation, signaling, and targeting of abl
kinases in cancer. Genes Cancer. 2012;3:436–46.
15. Migliorati G, Bartoli A, Nocentini G, Ronchetti S, Moraca R,
Riccardi C. Effect of dexamethasone on T-cell receptor/CD3
expression. Mol Cell Biochem. 1997;167:135–44.
Letter 2323
Leukemia (2019) 33:2324–2330
https://doi.org/10.1038/s41375-019-0452-6
Multiple myeloma gammopathies
Exome sequencing identifies germline variants in DIS3 in familial
multiple myeloma
Maroulio Pertesi1,2 ● Maxime Vallée1 ● Xiaomu Wei3 ● Maria V. Revuelta 4 ● Perrine Galia5,6 ● Delphine Demangel5,6 ●
Javier Oliver1,7 ● Matthieu Foll1 ● Siwei Chen3 ● Emeline Perrial8,9 ● Laurent Garderet10,11,12 ● Jill Corre13 ●
Xavier Leleu14 ● Eileen M. Boyle15 ● Olivier Decaux16,17,18 ● Philippe Rodon19 ● Brigitte Kolb20 ● Borhane Slama21 ●
Philippe Mineur22 ● Eric Voog23 ● Catherine Le Bris24 ● Jean Fontan25 ● Michel Maigre26 ● Marie Beaumont27 ●
Isabelle Azais28 ● Hagay Sobol29 ● Marguerite Vignon30 ● Bruno Royer30 ● Aurore Perrot31 ● Jean-Gabriel Fuzibet32 ●
Véronique Dorvaux33 ● Bruno Anglaret34 ● Pascale Cony-Makhoul35 ● Christian Berthou36 ● Florence Desquesnes37 ●
Brigitte Pegourie38 ● Serge Leyvraz39 ● Laurent Mosser40 ● Nicole Frenkiel41 ● Karine Augeul-Meunier42 ●
Isabelle Leduc43 ● Cécile Leyronnas44 ● Laurent Voillat45 ● Philippe Casassus46 ● Claire Mathiot47 ● Nathalie Cheron48 ●
Etienne Paubelle49 ● Philippe Moreau50 ● Yves–Jean Bignon51 ● Bertrand Joly52 ● Pascal Bourquard53 ● Denis Caillot54 ●
Hervé Naman55 ● Sophie Rigaudeau56 ● Gérald Marit57 ● Margaret Macro58 ● Isabelle Lambrecht59 ●
Manuel Cliquennois 60 ● Laure Vincent 61 ● Philippe Helias62 ● Hervé Avet-Loiseau63 ● Victor Moreno 64,65 ●
Rui Manuel Reis66,67 ● Judit Varkonyi68 ● Marcin Kruszewski69 ● Annette Juul Vangsted70 ● Artur Jurczyszyn71 ●
Jan Maciej Zaucha72 ● Juan Sainz 73 ● Malgorzata Krawczyk-Kulis74 ● Marzena Wątek 75,76 ● Matteo Pelosini77 ●
Elzbieta Iskierka-Jażdżewska78 ● Norbert Grząśko79 ● Joaquin Martinez-Lopez80 ● Andrés Jerez81 ● Daniele Campa82 ●
Gabriele Buda76 ● Fabienne Lesueur 83 ● Marek Dudziński84 ● Ramón García-Sanz 85 ● Arnon Nagler86 ●
Marcin Rymko87 ● Krzysztof Jamroziak75 ● Aleksandra Butrym88 ● Federico Canzian89 ● Ofure Obazee89 ●
Björn Nilsson2 ● Robert J. Klein 90 ● Steven M. Lipkin4 ● James D. McKay1 ● Charles Dumontet5,6,8,9
Received: 5 October 2018 / Revised: 4 February 2019 / Accepted: 8 February 2019 / Published online: 9 April 2019
© The Author(s) 2019. This article is published with open access
To the Editor:
Multiple myeloma (MM) is the third most common hemato-
logical malignancy, after Non-Hodgkin Lymphoma and Leu-
kemia. MM is generally preceded by Monoclonal Gammopathy
of Undetermined Significance (MGUS) [1], and epidemiolo-
gical studies have identified older age, male gender, family
history, and MGUS as risk factors for developing MM [2].
The somatic mutational landscape of sporadic MM has
been increasingly investigated, aiming to identify recurrent
genetic events involved in myelomagenesis. Whole exome
and whole genome sequencing studies have shown that MM
is a genetically heterogeneous disease that evolves through
accumulation of both clonal and subclonal driver mutations
[3] and identified recurrently somatically mutated genes,
including KRAS, NRAS, FAM46C, TP53, DIS3, BRAF,
TRAF3, CYLD, RB1 and PRDM1 [3–5].
Despite the fact that family-based studies have pro-
vided data consistent with an inherited genetic suscept-
ibility to MM compatible with Mendelian transmission
[6], the molecular basis of inherited MM predisposition is
only partly understood. Genome-Wide Association
(GWAS) studies have identified and validated 23 loci
significantly associated with an increased risk of devel-
oping MM that explain ~16% of heritability [7] and only a
subset of familial cases are thought to have a polygenic
background [8]. Recent studies have identified rare
germline variants predisposing to MM in KDM1A [9],
ARID1A and USP45 [10], and the implementation of next-
generation sequencing technology will allow the char-
acterization of more such rare variants.
In this study, we sought to explore the involvement of
rare germline genetic variants in susceptibility to MM.
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Within our discovery cohort of peripheral blood samples
(see Supplementary Methods) from 66 individuals from 23
unrelated families analyzed by WES, DIS3 (NM_014953)
was the only gene in which putative loss-of-function variants
were observed in at least two families. An additional cohort
of 937 individuals (148 MM, 139 MGUS, 642 unaffected
relatives and eight individuals with another hematological
condition) from 154 unrelated families (including the indi-
viduals in the discovery cohort) were screened for germline
variants in DIS3 using targeted sequencing (Supplementary
Table S1). In total, we detected DIS3 germline putative loss-
of-function variants in four unrelated families. The DIS3
genotypes for the identified variants were concordant
between WES and targeted sequencing (where available)
and independently confirmed by Sanger sequencing on
DNA extracted from uncultured whole blood. The variant
allele frequencies (VAF) were close to 50%, as expected of a
germline variant (Supplementary figure S1).
The DIS3 gene, located in 13q22.1, encodes for the cata-
lytic subunit of the human exosome complex, and is recur-
rently somatically mutated in MM patients [4, 5, 11, 12].
The somatic variants are predominantly missense variants
localized in the RNB domain mainly abolishing the
exoribonucleolytic activity [4, 13], and are often accom-
panied by LOH or biallelic inactivation due to 13q14
deletion, implying a tumor suppressor role for DIS3 in MM
[5, 12, 13].
The first DIS3 variant, observed in 2 affected siblings
(1 MGUS and 1 MM case) from family B (Fig. 1a), was
located in the splice donor site of exon 13 (c.1755+1G>T;
chr13: 73,345,041; GRCh37/hg19, rs769194741) (Supple-
mentary Figure S1a). It is predicted to abolish the splice donor
site and cause skipping of exon 13, introducing a premature
termination codon (p.Arg557Argfs*3) and result in a trun-
cated DIS3 protein that lacks part of the exonucleolytic active
RNB and S1 domains (Fig. 1b, c). The presence of this var-
iant in two siblings, implying Mendelian segregation, is
consistent with a germline, rather than somatic, origin. We
investigated whether a DIS3 transcript from the variant allele
is generated but is subsequently eliminated by Nonsense
Mediated Decay (NMD) by incubating Lymphoblastoid Cell
Lines (LCLs) derived from the two c.1755+1G>T allele
carriers with and without puromycin, which suppresses NMD.
The mRNA transcript corresponding to the variant allele was
clearly present in LCLs treated with puromycin in both car-
riers, whereas not detectable in untreated LCLs (Fig. 2a),
consistent with the variant allele being transcribed but sub-
sequently degraded via the NMD pathway. In line with this
observation, analysis of DIS3 mRNA expression by qRT-
PCR showed an average 50% reduced expression in the
c.1755+1G>T carriers (range 40.7−61.4%) as compared to
non-carriers (Fig. 2b). A second splicing variant (c.1883
+1G>C; chr13: 73,342,922; GRCh37/hg19) located in the
splice donor site of exon 14 within the RNB domain was
identified in a MM case from family D (Fig. 1a, b, Supple-
mentary figure S1c). However, the individual’s mother
(Q59), affected with amyloidosis, did not carry the variant,
implying that MM in the allele carriers’ maternal uncles is
unlikely to be explained by this DIS3 variant. Whether the
mRNA transcript encoded by this germline variant under-
goes NMD could not be explored due to lack of appropriate
material (LCLs, RNA).
A third DIS3 variant disrupting the wild-type termination
codon (stop-loss) (c.2875T>C; p.*959Gln; chr13:73,333,935;
GRCh37/hg19, rs141067458) (Fig. 1b, Supplementary Fig-
ure S1b) was identified in two unrelated families (A and C,
Fig. 1a). This variant is expected to result in a putative read-
through variant and a DIS3 protein with an additional 13 amino
acids in the C-terminus (p.*959Glnext*14). It was detected in 3
out of 4 affected siblings (2 MGUS (M63, O53) and 1 MM
case (O29)), as well as 5 unaffected relatives (N14, N13, L41,
M33 M50) from family A. The Mendelian segregation of this
variant in this pedigree is also consistent with germline origin.
An additional MM case from family C carried the variant, while
we were unable to assess the other MM-afflicted family
member (Fig. 1a). As expected of a stop-loss variant, NMDwas
not observed (data not shown), and gene expression analysis
showed no effect on DIS3 mRNA levels (Fig. 2b). However,
western blot analysis demonstrated that DIS3 protein levels
were markedly lower (~50%) in the p.*959Glnext*14 carrier
(O53, family A) compared to non-carriers (Fig. 2b, c).
Next, we sought to determine if rare, putative deleterious
variants in DIS3 were more frequent in an independent series
of MM cases compared to unaffected individuals. We per-
formed mutation burden tests between 781 MM cases and
3534 controls from the MMRF CoMMpass Study with WES
data available. After testing for systemic bias in this dataset
(see Supplementary Methods, Supplementary Figure S2), we
undertook a burden test for association between functional
DIS3 variants and MM. DIS3 putative functional variants
(truncating and likely deleterious missense variants, see Sup-
plementary Methods) were more frequent among MM
patients (30/781) than controls (72/3534) (OR= 1.92 95%
CI:1.25–2.96, p= 0.001). Although the p.*959Glnext*14
stop-loss variant was recurrently found in 10/781 MM cases
and 15/3534 controls (OR= 3.07 95%CI:1.38 to 6.87, p=
0.0007), it did not entirely explain the excess of DIS3 variants
among cases as there is evidence for association with other
putative functional variants (Supplementary Figure S3a). We
additionally genotyped the p.*959Glnext*14 stop-loss variant
in an independent series of sporadic MM cases and controls
from the IMMEnSE Consortium. While this variant was very
rare in this series (8/3020 MM cases relative to 3/1786 con-
trols), there was a consistent but non-significant association
between this variant and MM (OR= 3.15 95% CI: 0.74–
13.43 p= 0.122).
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To explore the functional consequence of germ-
line DIS3 variants, we compared MM tumor transcriptomes
from patients harboring germline (n= 21) and somatic (n=
96) DIS3 putative functional variants to non-carriers (n=
655). Differential expression analyses showed an enrichment
of pathways associated with global ncRNA processing and
translational termination in germline DIS3 carriers including
ncRNA processing, ncRNA metabolic process, translational
termination, and RNA metabolism. Among somatic DIS3
carriers, significantly enriched pathways include interferon
alpha/beta signalling, mRNA splicing, mRNA processing and
transcription (Supplementary Figure S3b, Supplementary
tables S3 and S4a–d). These findings are consistent with the
proposed DIS3 role in regulating mRNA processing [14] and
Fig. 1 DIS3 variants in MM cases. a Pedigrees from families carrying
a germline DIS3 variant. Available samples for screening are marked
with a “+” symbol. Families A and C carry the p.*959Glnext*14
(c.2875T>C) stop-loss variant. Family B carries the c.1755+1G>T
splicing variant and family D carries the c.1883+1G>C splicing var-
iant. The genotype of all screened individuals is shown on each ped-
igree. WT: wild type. b, c Schematic representation of identified
germline and somatic variants in the distinct DIS3 protein domains. b
Germline variants were identified through WES and targeted
resequencing in families with reoccurrence of MM/MGUS as well as
in a collection of sporadic MM cases (MMRF CoMMpass Study). The
DIS3 variants discussed in the present study are depicted with a star on
the upper part of the figure. c Somatic DIS3 variants were identified in
sporadic MM cases from the MMRF CoMMpass Study. We observe
that in contrast to the clustering of somatic DIS3 missense variants in
the RNB and PIN domains, germline variants are scattered throughout
the gene and consist of splicing, stop-loss and missense variants
2326 Letter
more specifically mRNA decay, gene expression and small
RNA processing [15]. We also observed that, several long-
intergenic non-protein coding RNAs, non-coding and anti-
sense RNAs were significantly enriched among DIS3 carriers
(Supplementary table S5a, b) supporting previous studies that
demonstrate an accumulation of transcripts from non-protein
coding regions, snoRNA precursors and certain lncRNAs in
DIS3 mutant cells, along a general deregulation of mRNA
levels probably due to the sequestration of transcriptional
factors from the accumulated nuclear RNAs [16].
To our knowledge, this is the first observation of germline
DIS3 likely deleterious variants in familial MM and our
results suggest that the involvement of DIS3 in MM etiology
may extend beyond somatic alterations to germline suscept-
ibility. We reported rare germline DIS3 variants in ~2.6% of
our cohort of families with multiple cases of MM and MGUS
(4/154). The germline variants described here are predicted to
have loss-of-function impact on DIS3. Consistent with this,
the 1755+1G>T (rs769194741) splicing variant induces
NMD and results in reduced DIS3 mRNA expression, sup-
porting the proposal that DIS3 is acting as a tumor suppressor
gene in MM [13]. Moreover, the c.2875T>C (rs141067458)
stop-loss variant (p.*959Glnext*14) results in reduced DIS3
protein expression suggesting that the mutant allele is trans-
lated but degraded shortly after. Notably, in contrast to the
clustering of somatic DIS3 mutations in the PIN and RNB
domains, germline variants identified both in familial and
sporadic MM cases are scattered throughout the gene (Fig. 1b,
c). Despite the fact that these variants do not segregate per-
fectly with MM in the identified families and the rarity of
DIS3 germline likely deleterious variants limits our statistical
power, the subsequent mutation burden and transcriptome
Fig. 2 DIS3 c.1755+1G>T splicing variant results in nonsense-
mediated mRNA decay (NMD) and affects mRNA expression, while
the c.2875C>T (p.*959Glnext*14) stop-loss variant affects protein
levels. a LCLs from patients E18 and E28 (not shown) carrying the
c.1755+1G>T splicing variant were cultured with and without pur-
omycin. The chromatogram from treated cells (with puromycin)
showed a mixture of the wild-type and mutant transcript lacking exon
13, which was not detected in the non-treated cells (without pur-
omycin). Thus, the mutant transcript is degraded by NMD. b Box plot
representing the relative DIS3 mRNA expression in c.1775+1G>A
(n=2) and p.*959Glnext*14 (n= 1) carriers compared to non-carriers
(n= 4). All reactions were performed in triplicates. c Western blot
with an anti-DIS3 antibody was performed in LCLs from one p.
*959Glnext*14 carrier and two wild-type individuals (anti-GAPDH
antibody as internal control). The relative DIS3 expression in the p.
*959Glnext*14 carrier was reduced by 50% compared to non-carriers,
suggesting that the mutant allele is translated but degraded shortly after
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analyses provided supportive data towards DIS3 acting as an
“intermediate-risk” MM susceptibility gene.
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To the Editor:
Germline predispositions are involved in the development
of 5% of childhood leukemias [1], although their con-
tribution is believed to be higher. However, to reveal the
full spectrum of pathogenic germline variants, individua-
lized genomic patient analyses, in the context of the
respective familial background (trio-calling), are needed.
Here, we present the finding of a germline predisposition
to B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
that is exerted through two synergizing, separately transmitted
germline variants (JAK2 p.G571S and STAT3 p.K370R). We
demonstrate a modest proliferation potential of JAK2 p.
G571S, which is additionally increased by STAT3 p.K370R
through rewiring of intracellular signaling pathways and show
that JAK2 G571S can rescue a STAT3 p.K370R-induced cell
cycle arrest. Protein modeling of both variants structurally
underlines the observed phenotypes. Furthermore, JAK2 p.
G571S could be identified in a second patient with Down
syndrome ALL, emphasizing its significance as a recurrent
synergizing germline susceptibility variant.
Taken together, we describe JAK2 p.G571S as a novel
germline predisposition in BCP-ALL. Moreover, our data
emphasize the synergistic interplay between separately
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transmitted germline risk variants that can render B-cell
precursors susceptible to additional somatic hits, allowing
BCP-ALL development. Expanding this knowledge is a
crucial step towards targeted treatments as well as precision-
prevention programs.
Acute lymphoblastic leukemia (ALL) is the most com-
mon pediatric cancer (4/100,000) under the age of 15, with
the majority of cases affecting B-cell precursors (BCP-ALL)
[2]. Although survival rates exceed 90%, it remains a sig-
nificant cause of death in young children. Thus, to develop
novel individualized therapeutic approaches, or even better,
to envision precision-prevention programs—in particularly
for subtypes of high-risk ALL, elucidation of the tumor
genetics are fundamental [3]. In this regard, inherited
germline variants are of special interest. Recently, novel
germline predisposition syndromes have been described [4],
and current studies increasingly highlight the importance of
trio-calling analyses in childhood cancer [5, 6].
In this study, we performed trio-calling and describe a
novel scenario for lymphoid malignancies, in which two
susceptibility loci are inherited—a paternal one and a
maternal one—and both act synergistically in the same
signaling pathway, thereby forming a susceptible B-cell
precursor compartment that is prone to secondary mutations
driving BCP-ALL.
Utilizing whole-exome sequencing we identified two
concomitant germline single-nucleotide variants (SNVs)
affecting the JAK2/STAT3 pathway in a boy with BCP-
ALL (Fig. S1A). The JAK2 variant, rs139504737 (c.1711G
> A), leads to an aminoacid substitution from glycine to
serine (p.G571S) and is rarely found within the general
population (minor allele frequency (MAF) < 0.01). Inter-
estingly, the same JAK2 p.G571S germline variant was
identified in a Down syndrome (DS-ALL) patient from an
independent family (Fig. 1a). The second variant found in
the BCP-ALL patient, constitutes an extremely rare, and so
far for leukemia undescribed, missense mutation in the
STAT3 gene (c.1109 A > G), causing an exchange of lysine
to arginine (p.K370R). While JAK2 p.G571S was trans-
mitted from the father, STAT3 p.K370R was inherited from
the mother’s side (Fig. 1a). Both variants are located in
functionally relevant domains, with STAT3 p.K370R being
Fig. 1 a Pedigree of two independent families harboring JAK2 p.
G571S. The ALL patients are marked with a red triangle, while the
transmission of the identified target mutations is highlighted with red
symbols (JAK2= circle; STAT3=+; trisomy 21= #). b Domain
organization of JAK2 and STAT3 proteins. Identified mutations (red)
and the known activating JAK2 mutation p.V617F (black), which was
used as a control, are highlighted. c Overview of the STAT3-WT
(gray) with bound DNA (orange). The blue rectangle indicates the
region with the residues of interest (sticks). A close-up depicts the
mutated region in STAT3-WT (gray) and the p.K370R variant (dark
green). While in the STAT3-WT, p.K370 only interacts with p.E455,
p.R370 of the p.K370R variant interacts with both p.E442 and p.E455
as indicated by the yellow lines. The mutation of lysine to arginine
also distorts the local backbone conformation. d Homology model of
the p.G571S variant in the JAK2 protein (green). P.S571 (sticks) is
located in a loop between two β-strands next to p.Y570 (sticks), which
is one of the most important phosphorylation sites in JAK2
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localized in the DNA-binding domain and JAK2 p.G571S in
the pseudo-kinase domain, respectively (Fig. 1b).
Furthermore, 11 somatic mutations were identified in the
BCP-ALL (Fig. S1B), with a missense mutation in the
CEP89 gene (p.K138T) being the only tumor specific
somatic variant. In addition, CytoScan™-HD analysis
revealed loss of CDKN2A and IKZF1 loci, which groups the
patient into the recently described IKZF1plus subgroup that
was shown to have a particularly poor outcome [7]
(Fig. S1C). Moreover, a somatic JAK2 rearrangement was
detected by cytogenetic analysis in the second JAK2 allele.
While molecular genetic analysis could rule out a classical
JAK2 fusion with ETV6, BCR, or PAX5, the actual fusion
partner was not identified. The patient was enrolled into the
AIEOP-BFM 2009 therapy protocol, responded poorly to
therapy (prednisone-poor response at day 8, nonremission at
day 33) and underwent hematopoietic stem cell transplan-
tation from a matched unrelated donor after achieving first
remission (MRD level < 10−4).
To understand potential phenotypic influences of both
mutant proteins on a structural level, we generated homol-
ogy models of the mutated pseudokinase domain of JAK2
and the mutated STAT3, and compared the models to their
respective wild types.
STAT3 p.K370R is located in a loop adjacent to the
DNA binding site (Fig. 1c). Moreover, STAT3 p.K370 is
an important site for acetylation, which enables STAT3’s
interaction with RELA, in turn promoting further
downstream signaling [8]. In the deacetylated state,
STAT3 p.K370 interacts with p.E455 in a β-sheet. Sub-
stitution of lysine to arginine at position p.370 has two
implications: first, the arginine can interact with both p.
E455 and p.E442 simultaneously, that way strengthening
the interaction in the β-sheet. Second, in contrast to
lysine, arginine cannot be acetylated. This combination
leads to a constitutively non-acetylated form of STAT3 at
position p.370, which was shown to have functional
consequences in its interaction capacity with various
signaling partners in HEK293T cells [8]. Furthermore,
the STAT3 p.K370R protein did not show an activating
phenotype in STAT3 reporter luciferase assays in
HEK293T cells (Fig. S2A). This is in line with the
structural modeling, suggesting impaired acetylation
rather than phosphorylation (Fig. S2B).
JAK2 p.G571 is located in a 12-residue loop connecting
2 β-strands (Fig. 1d), adjacent to p.Y570, one of the most
important phosphorylation sites in JAK2. This suggests an
influence on the phosphorylation of p.Y570 either through
steric hindrance, interactions of the serine sidechain or
changes in the backbone conformation near p.Y570.
Its unique position affecting amino acid 571, which lies
adjacent to the p.Y570 residue that downregulates kinase
activity via autophosphorylation hints at a potential
functional mechanism of p.G571S by inhibiting p.Y570-
directed negative feedback.
To assess the cooperative potential of both variants,
BaF3 depletion assays were carried out. In normal BaF3
cells, neither STAT3 p.K370R nor JAK2 p.G571S protein
expression alone were sufficient to induce IL-3 independent
growth, although immunoblot analyses confirmed increased
p-STAT3 levels in cells expressing both JAK2 p.G571S and
STAT3 p.K370R (Fig. 2a). Since dimerization by a cyto-
kine receptor facilitates the constitutive activation of JAK2
mutants, we further transfected BaF3 cells which expressed
human CRLF2 and the IL7R alpha chain (leading to the
formation of the heterodimeric receptor for thymic stromal
lymphopoietin (TSLP) [9]) with the identified target var-
iants. In BaF3/CRLF2-IL-7RWT cells, JAK2 p.G571S
protein expression conferred IL-3 independent growth.
Moreover, the combination of both mutant proteins (JAK2
p.G571S+ STAT3 p.K370R) showed a mild but significant
growth advantage starting 2 days after IL-3 withdrawal
(Fig. 2b). Immunoblot analysis revealed high-p-AKT levels
in cells expressing JAK2 p.G571S, which was changed to
p-STAT3 through additional expression of STAT3 p.
K370R. Since hyperactivation of p-AKT negatively affects
precursor B-cell survival [10], the here observed signal
rewiring indicates a synergistic effect of both variants by
balancing out signaling strengths.
Besides the cooperating capacity of both identified germ-
line variants, we further observed that the STAT3 p.K370R
mutant protein alone changed the phenotype of the cells in
culture, with an accumulation of enlarged BaF3 cells. Sur-
prisingly, this phenotype was reversed in the double mutant
cells expressing both STAT3 p.K370R and JAK2 p.G571S
(Fig. S2C). Cell cycle analysis was in line with this obser-
vation, showing a significant increase in >4n cells (p=
0.0009), while those in the G-1 phase were significantly
decreased (p= 0.0031) in STAT3 p.K370R expressing BaF3
cells compared to STAT3-WT cells (Fig. 2c). Again, this
phenotype was reduced in BaF3 cells transfected with both
mutants simultaneously (G1 phase p= 0.0026; > 4n, p=
0.0032). In line with the reversed cell cycle phenotype in the
double mutant cells, immunoblot analysis of the different
conditions confirmed increased p-CDC-2, p-CyclinB1/
Cyclin-B1, and Cyclin-A2 in BaF3 cells expressing both
JAK2 p.G571S and STAT3 p.K370R compared to STAT3 p.
K370R alone (Fig. 2c). Taken together, STAT3 p.K370R
conferred a cell cycle arrest in BaF3 cells which is consistent
with a loss-of-function phenotype in the STAT3 reporter
luciferase assay and the structural modeling.
These data suggest that the two mutations can act in
concert to exert a germline susceptibility toward BCP-ALL
development by the accumulation of a susceptible precursor
compartment. This compartment might be prone to acquire
additional secondary lesions in IKZF1 and CDKN2A or
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alterations of the JAK2 WT allele, which act as somatic
oncogenic drivers leading to malignant growth.
Activation of the JAK-STAT pathway is known to be a
key event in a variety of hematological malignancies. JAK2
p.V617F leads to constitutively active STAT5 signaling in
about 80% of patients suffering from myeloproliferative
neoplasms [11], and a high frequency of somatic rearran-
gements or SNVs activating JAK2 are found in Ph-like
ALL [12] and DS-ALL [13, 14]. However, germline JAK2
mutations particularly in BCP-ALL are rare. Here, we
identified a second patient harboring germline JAK2 p.
G571S in a DS-ALL cohort of 88 patients (Fig. 1a and
Fig. S3) [14]. A major proportion of DS-ALL shows high
expression of CRLF2 and somatic JAK/STAT pathway
activation [15]. Although the analyzed DS-ALL patient did
not express a P2RY8-CRLF2 transcript or show a CRLF2
p.232 mutation, he may harbor an activating translocation
of CRLF2 into the IGH chain locus. However, due to the
lack of patient material we could not test this hypothesis.
Therefore, though CRLF2 activation in association with
JAK2 p.G571S and trisomy 21 seems highly likely, we
cannot confirm an active CRLF2 status in this patient.
Nevertheless, the germline JAK2 p.G571S mutation in
combination with trisomy 21 can be a complementary
scenario of two germline variants acting in synergy to
render cells susceptible to additional somatic alterations that
can drive ALL development. This insight further strength-
ens the unique and important role of weak oncogenic
germline risk variants (e.g., JAK2 p.G571S) and how they
can synergize with additional low-penetrance mutations/
alterations to predispose to ALL development.
Fig. 2 a Top: Proliferation curve showing prolonged survival for BaF3
cells expressing either JAK2 p.G571S protein alone or both JAK2 p.
G571S and STAT3 p.K370R proteins. Transfected BaF3 cells were
cultured in media without IL-3 for 7 days and their proliferation
measured every day using trypan blue. JAK2 p.V617F serves as
positive control. Values represent the mean out of three replicates with
essentially identical datasets (n= 3). Bottom: Immunoblot analysis of
BaF3 cells expressing STAT3-WT, STAT3-p.K370R, JAK2-p.G571S,
JAK2-p.V617F, or STAT3-p.K370R+JAK2-p.G571S. Depicted are
p-STAT3 and p-STAT5 levels of the respective cells. Total STAT3,
STAT5, as well as beta-ACTIN serve as loading controls (n= 2). b
Top: Proliferation curve showing prolonged survival for BaF3/
CRLF2-IL-7RWT cells expressing either JAK2 p.G571S alone or both
JAK2 p.G571S and STAT3 p.K370R. Cells harboring both mutants
show a significantly higher proliferation rate compared to cells
expressing JAK2 p.G571S, starting at day 2 after IL-3 withdrawal
(calculated by Student’s t test: p values are indicated). Cells were
cultured as described in (a) (n= 3). Bottom: Immunoblot of BaF3/
CRLF2-IL-7RWT cells harboring Empty Vector (EV), STAT3-WT,
STAT3-p.K370R, JAK2-p.G571S, or STAT3-p.K370R+JAK2-p.
G571S expression plasmids. Depicted are p-STAT3, p-STAT5, and p-
AKT levels of the respective cells. Total STAT3, STAT5, AKT, as
well as GAPDH serve as loading controls (n= 2). c Top: Cell cycle
analysis showing an accumulation of >4n, as well as a reduction of
cells in the G1-phase for STAT3 p.K370R expressing BaF3 cells, as
compared to cells expressing STAT3-WT or STAT3 p.K370R+JAK2
p.G571S. p Values are indicated as calculated by Student’s t test (n=
3). Bottom: Immunoblot depicting the expression of the cell cycle
related proteins CDC2 and Cyclin-B1/B2/A2 in BaF3 cells expressing
either EV, STAT3-WT, STAT3-p.K370R, JAK2-p.G571S, or both
mutant proteins. GAPDH serves as loading control
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Thus, we suggest a scenario where STAT3 p.K370R or
trisomy 21 in synergy with JAK2 p.G571S prime precursor
B-cells susceptible for oncogenic transformation through
the acquisition of secondary somatic hits. This can be a
rational explanation why parents of affected children are
healthy throughout life, whereas children who carry both
germline variants develop ALL. Increasing knowledge of
inherited di-/polygenic variants will be of great importance
for the development of novel precision-prevention approa-
ches in the future.
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To the Editor:
The signal transducer and activator of transcription 5B
(STAT5B), downstream of IL-15 signaling and Janus kinase
(JAK)1, and 3-mediated activation, is a master regulator
of development, survival, and function of innate and innate-
like lymphocytes (including natural killer (NK) and NKT
cells) [1–3]. Gain-of-function mutations in the SH2 domain of
human STAT5B, especially STAT5BN642H, are associated
with aggressive forms of CD56+ T cell (NKT) and NK cell
lymphomas/leukemias [4–6]. We described a mouse model
expressing human (h)STAT5BN642H under the Vav-1 pro-
moter, which develops severe CD8+ T cell neoplasia [7].
Here, we explore the ability of hSTAT5BN642H to serve as
an oncogenic driver in innate lymphocyte neoplasms.
We found an increase in absolute NK cell numbers in the
spleen of T cell-diseased hSTAT5BN642H transgenic com-
pared to wild-type (WT) mice (Fig. 1a), despite the relative
decrease of the proportion of NK cells among splenic lym-
phocytes (Fig. S1A), while nonmutant hSTAT5B control
mice showed intermediate NK cell numbers (Fig. 1a,
Fig. S1A). No significant differences in NK cell numbers
were observed in the bone marrow (BM) between genotypes
(Fig. S1B). In addition, both hSTAT5B and hSTAT5BN642H
mice showed a similar increase in the proportion of mature
NK cells (CD27−CD11b+ and KLRG1+) in the spleen
(Fig. S1C, D). These findings suggest that the enforced
expression of nonmutant hSTAT5B is sufficient to boost NK
cell maturation, which is not further enhanced by introducing
the activating hSTAT5B mutation. We hypothesized that any
phenotypic alterations affecting innate lymphocytes might
be masked by the hSTAT5BN642H-driven aggressive CD8+
T cell disease established in hSTAT5BN642H mice at the age
of 6–8 weeks [7]. To explore the potential of hSTAT5BN642H
to promote NK cell expansion in vivo, we transplanted CD3-
depleted BM from hSTAT5BN642H or hSTAT5B mice
in immune-deficient Rag2−/−γc−/− recipient mice. Using this
approach, we observed an enhanced expansion of NK cells
in the blood of hSTAT5BN642H compared to hSTAT5B-
transplanted recipients over a time course of 4 weeks
(Fig. 1b). Long-term analysis of NK cells in hSTAT5BN642H-
transplanted mice was not possible due to expansion of
residual CD8+ T cells (Fig. S1E, F), which forced us to ter-
minate the experiment. However, after 4 weeks, increased
numbers of NK cells were also detected in the spleen upon
transplantation of CD3-depleted hSTAT5BN642H compared
to hSTAT5B BM (Fig. S1G).
To investigate long-term effects of hSTAT5BN642H on
innate lymphocytes, we sorted Lineage (Lin)− (CD3/B220/
Ter119/Gr1/CD11b) Sca1−c-Kit−CD127−CD8− cells. This
cellular fraction is devoid of hematopoietic stem cells, com-
mon lymphoid progenitors, and CD8+ T cells and was
obtained from hSTAT5BN642H or hSTAT5B BM for further
transplantation into Rag2−/−γc−/− recipient mice. We mon-
itored NK and T cell numbers in the blood over a period of
5 weeks. Again, a modest increase but subsequent drop in
NK cell numbers in mice transplanted with hSTAT5BN642H
compared to hSTAT5B BM cells was observed (Fig. S1H),
whereas we failed to detect CD8+ T cells in the blood of the
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recipient animals (Fig. S1I). This indicated that our sorting
strategy successfully eliminated CD8+ T cell disease, but did
not allow us to uncover persistent hSTAT5BN642H-mediated
NK cell expansion. Of note, after 4.5–10 months all three
hSTAT5BN642H-recipient mice (#1–3) developed a rapidly
progressing disease, characterized by expansion of CD3
+NK1.1+ NKT cells in blood, BM, spleen, and liver (Fig. 1c,
Table S1). Disease development was restricted to
transplantation of mutant hSTAT5B cells and was not
detected upon transplantation of hSTAT5B BM, despite fol-
lowing up these animals for 10 months.
To investigate, whether hSTAT5BN642H NKT cells are
indeed transformed and fulfill the criteria of being
leukemic, we started to perform serial whole BM transplants
from the earlier diseased recipient #1 (survival: 133 d)
with the presumably more aggressive disease. To do so,
Letter 2337
we transplanted BM containing 1 × 106 NKT cells into
immune-deficient Rag2−/−γc−/− or NSG-recipient mice.
This serial transplantation approach was continued for a
total of six rounds. The first two rounds were performed to
maintain and amplify the NKT cell disease. We confirmed
the presence of the hSTAT5BN642H transgene in a diseased
mouse (Fig. S1J). Upon the 3rd to the 6th round of serial
transplant, we characterized the manifested disease as an
aggressive leukemia accompanied by hepatosplenomegaly
(Fig. 2a), increased white blood cell (WBC) counts
(Fig. S2A) and a high frequency of NKT cells in blood,
BM, spleen, and liver (Fig. S2C, D) with a mean survival of
17.6 days (Fig. S2B). Infiltration of leukemic cells into
various organs was confirmed by histological analysis
(Fig. S2E). In the 6th round, a titration of transplanted NKT
cell numbers was performed. Disease severity at the end
point was comparable, while a delay of 3 days occurred
between each titration step (Fig. 2a, Fig. S2A–D). Despite
the increased disease latency in recipients #2 (survival:
294 d) and #3 (survival: 301 d), the disease could also be
serially transplanted giving rise to a similarly aggressive
disease (Fig. S3A–H) as for recipient #1.
A more detailed characterization of surface markers on
transformed NKT cells from the serially transplanted disease
of recipient #1 verified expression of the T cell receptor (TCR)
β chain, while CD4, CD8, and TCRγδ expression was not
detected. Leukemic cells also stained positive for CD122 and
the NK cell markers NKp46 and DX5. No interaction with the
CD1d tetramer was observed (Fig. 2b). This surface marker
profile corresponds to previously described CD1d-independent
NKT cells [8, 9], which were recently identified as a source
for CD3+NK1.1+ T-cell large granular lymphocyte (T-LGL)
leukemia in IL-15 transgenic mice [10]. In analogy to our
NKT cell leukemia model, human CD56+ T-LGL leukemia
cells were also shown to express NKp46 [10]. Additionally,
CD3+CD56+ blasts in human T-LGL leukemia express CD8
[4]. Interestingly, we found CD8 expressed on a subset of
hSTAT5BN642H NKT leukemia cells in the two later diseased
recipients #2 and #3, but not in recipient #1 (Table S1).
Furthermore, the serially transplanted leukemic NKT cells
from recipient #1 were largely negative for activating and
inhibitory NK cell receptors, except for Ly49G2 and KLRG1
(Fig. S4A), but stained positive for CD43, CD44, and CD69,
while lacking CD62L (Fig. S4A). In summary, this surface
receptor expression profile is consistent with an activated
phenotype comparable to the leukemic blasts found in IL-15
transgenic mice [11]. The fact that IL-15 transgenic mice
develop NK1.1+ T-LGL (NKT) or NK cell leukemia [10, 11]
supports the importance of the IL-15-STAT5 axis for the
transformation of subsets of innate lymphocytes. The occur-
rence of leukemia with an NKT cell profile in our model
suggests that additional IL-15-derived signals, independent of
STAT5, may be required for NK cell transformation. In
contrast to IL-15 transgenic mice, in which transformation is
restricted to innate-like lymphocytes, NKp46+ NKT cell
disease required the absence of classical CD8+ T cells bearing
mutant hSTAT5B in vivo. As NKp46+ NKT cells represent a
minor population [10], the higher number of CD8+ T cells
may simply outcompete potentially transformed NKT cells.
Alternatively, it is possible that CD8+ T cells actively sup-
press the development of NKT cell tumors providing a hostile
tumor microenvironment.
hSTAT5BN642H-driven CD8+ T cell disease is susceptible
to JAK1/JAK2 inhibition by Ruxolitinib treatment [7].
As JAK inhibitors have also been suggested as therapeutic
strategy for NK/T-cell lymphoma and aggressive NK cell
leukemia [6, 12], we transplanted NSG mice with
hSTAT5BN642H NKT leukemia cells and treated them with
ruxolitinib for 3 weeks. Treatment attenuated disease severity
and decreased hepatosplenomegaly and WBC counts com-
pared to the control group (Fig. 2c and Fig. S4B).
Although initial attempts to grow transformed NKT cells
in vitro failed, after 6–8 weeks we detected outgrowth
of hSTAT5BN642H NKT cell lines from cultured hepatic
leukocytes of three out of nine NSG mice from different
serial transplant rounds from recipient #1 (Table S2,
Fig. S5A). Two cell lines, derived from the same mouse
cultured without or with IL-2 (4165_1 and 4165_2,
respectively), were treated with Ruxolitinib and remained
sensitivity towards it (IC50 of 83 and 72.5 nM, respectively)
(Fig. S5B). Furthermore, these cell lines could give rise
to leukemia when injected into immune-competent Ly5.1/
CD45.1+ mice (Fig. S5C–E).
In this study, we identify STAT5BN642H as an oncogenic
driver in innate-like lymphocytes. Our novel NKT leukemia
Fig. 1 hSTAT5BN642H drives limited NK cell expansion and gives rise
to leukemia characterized by expansion of NKT cells. a Absolute
numbers (#) of splenic NK cells (CD3−NK1.1+NKp46+) were deter-
mined in WT, hSTAT5B, and hSTAT5BN642H mice by flow cytometry
(n= 10 (WT), n= 8 (hSTAT5B), n= 7 (hSTAT5BN642H) pooled from
four independent experiments). Symbols represent results from indi-
vidual mice, horizontal lines indicate mean ± SEM. *p < 0.05, one-way
ANOVA. b CD3-depleted bone marrow (BM) from hSTAT5B or
hSTAT5BN642H mice was transplanted into Rag2−/−γc−/− recipient
mice (n= 3) and NK cell numbers were monitored in the blood weekly
for 4 weeks by flow cytometry. One representative experiment from
two independent experiments is shown. Symbols represent results from
individual mice, horizontal lines indicate mean ± SEM. *p < 0.05,
unpaired t-test with Welch’s correction. c Lineage (Lin)− Sca1−c-Kit
−CD127−CD8− cells were sorted from BM of hSTAT5B or
hSTAT5BN642H mice and 1 × 105 cells were injected into Rag2−/−γc−/−
recipient mice (n= 3). Percentages of NKT cells (CD3+NK1.1+)
among living cells in blood, BM, spleen, and liver were analyzed by
flow cytometry from the diseased hSTAT5BN642H-transplanted reci-
pient mice (#1–3) (days of survival after transplant are indicated in
brackets) and a healthy hSTAT5B-transplanted control mouse. Dot
plots are shown. We could not analyze NKT cell frequency in the
spleen of mouse #3 (marked by *), due to limited quality of spleen
tissue. Analysis was performed when the diseased mice reached the
humane endpoint
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Fig. 2 hSTAT5BN642H induces leukemia of CD1d-independent NKp46+
NKT cells, which is serially transplantable and sensitive to Ruxolitinib
treatment. a BM from NKT cell-diseased recipient #1, transplanted
with sorted hSTAT5BN642H BM cells, was serially transplanted into
Rag2−/−γc−/− or NSG-recipient mice for six rounds. Whole BM, con-
taining 1 × 106 transformed NKT cells, was transplanted. Of note, in
the 6th serial transplant (ST) round a titration of the number of trans-
planted NKT cells was performed, with two mice each receiving BM
containing 1 × 106 (circle), 0.3 × 106 (rectangle), or 0.1 ×106 (triangle)
NKT cells. Representative images of liver and spleen from an
hSTAT5BN642H NKT cell-transplanted (6th ST) compared to a non-
transplanted NSG mouse are shown; line denotes 1 cm (left panel).
Relative liver and spleen to body weights are shown for the 3rd to 6th
ST (n= 3 (3rd ST), n= 4 (4th ST), n= 13 (5th ST), n= 6 (6th ST))
(right panel). Symbols represent results from individual mice, horizontal
lines indicate mean ± SEM. ***p < 0.001, unpaired t-test with Welch’s
correction. b Surface marker expression on transformed hSTAT5BN642H
NKT cells was analyzed by flow cytometry. Representative histograms
from BM NKT cells of one diseased NSG mouse (4th ST) are
shown (unfilled histogram: negative staining control; filled histogram:
surface staining). Numbers depict the mean of MFI (median fluorescence
intensity, normalized to negative staining control) ± SEM from three
diseased mice (4th ST). a, b Analysis was performed when the
diseased mice reached the humane endpoint. c NSG mice were
transplanted with BM containing 1 × 106 hSTAT5BN642H NKT cells
(from 5th ST) and treated with Ruxolitinib (RUXO) (85mg/kg body
weight, twice daily) or vehicle control (Nutella®) (n= 4 per treatment),
starting 1 day after NKT cell transplant for 21 days (one experiment).
Representative images of liver and spleen to body weights from
untreated control and RUXO-treated mice are depicted; line denotes 1 cm
(left panel). Relative liver and spleen weights were analyzed in the
mice after 3 weeks of treatment (right panel). Symbols represent results
from individual mice, horizontal lines indicate mean ± SEM. **p < 0.01,
***p < 0.001, unpaired t-test
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model, which is serially transplantable and inducible by
frozen material or from cell lines, recapitulates human
CD56+ LGL leukemia and provides new means for trans-
lational research. It will allow a deeper understanding of
mechanisms driving NKT leukemia progression and main-
tenance as well as facilitate finding new therapeutic options.
This is of vital importance as the STAT5BN642H mutation in
CD56+ LGL leukemia patients is associated with a parti-
cularly aggressive chemo-refractory phenotype [4].
Acknowledgments We thank Sabine Fajmann and Philipp Jodl for
great technical support and Manuela Kindl for maintaining and mon-
itoring the mice.
Funding The work was supported by the Austrian Science Fund FWF
grant SFB-F06105 to RM and SFB-F06107 to VS and FWF grant
W1212 to VS.
Author contributions VS initiated and supervised the study. KK,
AWS, and BM designed the experiments; KK, AWS, BM, DP, and NL
performed the experiments; MPM and TS provided technical support;
KK and GH analyzed the data; RM provided the mouse model. KK
and VS wrote the manuscript. AWS, BM, DP, TS, and RM revised the
manuscript.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict
of interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe
T, et al. A novel Ncr1-Cre mouse reveals the essential role
of STAT5 for NK-cell survival and development. Blood.
2011;117:1565–74.
2. Gotthardt D, Sexl V. STATs in NK-cells: the good, the bad,
and the ugly. Front Immunol. 2017;7:1–8.
3. Villarino AV, Sciumè G, Davis FP, Iwata S, Zitti B,
Robinson GW, et al. Subset- and tissue-defined STAT5
thresholds control homeostasis and function of innate lymphoid
cells. J Exp Med. 2017;214:2999–3014.
4. Rajala HLM, Eldfors S, Kuusanm H, Van Adrichem AJ,
Olson T, Lagstr S, et al. Discovery of somatic STAT5b
mutations in large granular lymphocytic leukemia. Blood.
2013;121:4541–51.
5. Küçük C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W,
et al. Activating mutations of STAT5B and STAT3 in
lymphomas derived from γδ-T or NK cells. Nat Commun.
2015;6:6025.
6. Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA,
Eldfors S, et al. Aggressive natural killer-cell leukemia mutational
landscape and drug profiling highlight JAK-STAT signaling as
therapeutic target. Nat Commun. 2018;9:1–12.
7. Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R,
Grundschober E, Javaheri T, et al. STAT5B N642H is a
driver mutation for T cell neoplasia. J Clin Invest. 2018;128:
387–401.
8. Maeda M, Shadeo A, Macfadyen AM, Takei F. CD1d-
independent NKT cells in β 2 -microglobulin-deficient
mice have hybrid phenotype and function of NK and T cells.
J Immunol. 2004;172:6115–22.
9. Farr AR, Wu W, Choi B, Cavalcoli JD, Laouar Y. CD1d-
unrestricted NKT cells are endowed with a hybrid function far
superior than that of iNKT cells. Proc Natl Acad Sci USA.
2014;111:12841–6.
10. Yu J, Tridandapani S, Caligiuri MA, Yu J, Mitsui T, Wei M,
et al. NKp46 identifies an NKT cell subset susceptible to
leukemic transformation in mouse and human. J Clin Invest.
2011;121:1456–70.
11. Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J,
Curphey D, et al. A novel mouse model for the aggressive variant
of NK cell and T cell large granular lymphocyte leukemia. Leuk
Res. 2010;34:1–14.
12. Hee YT, Yan J, Nizetic D, Chng W. LEE011 and
ruxolitinib: a synergistic drug combination for natural
killer/T-cell lymphoma (NKTCL). Oncotarget. 2018;9:
31832–41.
2340 Letter
